Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ALK-1/ACVRL1 Protein, 1mg  

Recombinant human ALK-1/ACVRL1 Protein, 1mg

Recombinant human ALK-1 /ACVRL1 Protein (rhALK1), Asp22-Gln118 was expressed in human 293 cells (HEK293), His Tag

Synonym
recombinant, human, protein ACVRL1, ACVRL-1, ACVRLK1, ALK-1, ALK1, HHT, HHT2, HHT-2, ORW2, ORW-2, SKR3, SKR-3, TSR-I

More details

AL1-H5227-1K

Availability: within 7 days

1 800,00 €

Background
Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene[1-2]. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic [3]. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells[4].

Source
Recombinant Human ALK-1, His Tag (AL1-H5227) is expressed from human 293 cells (HEK293). It contains AA Asp 22 - Gln 118 (Accession # NP_000011.2).
Predicted N-terminus: Asp 22

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 11.5 kDa. The protein migrates as 22-28 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhALK1 by the LAL method.

Purity
>97% purity as determined by SDS-PAGE of reduced rhALK1.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

References

(1) Ten Dijke P, Ichijo H, et al. (Oct 1993). Oncogene 8 (10): 2879–87
(2) Johnson DW, Berg JN, et al.(Jul 1996). Nat Genet 13 (2): 189–95
(3) Lawlor MW, Read BP, et al. (Feb.2011). Am J Pathol. 178(2):784-93
(4) Mitchell D,et al.(Feb. 2010). Mol Cancer Ther.. 9(2):379-88